Skip to main content

Table 1 Patients’ characteristics

From: Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer

Total number of patients, n 114
Age, years, Median (Range) 70 (40-96)
Gender, male/female 95/19
Recurrence within 24 months, n (%) 38 (33.0)
pT Stage of first recurrence within 24 months  
 pTa 25 (65.8)
 pT1 5 (13.1)
 ≥ pT2 3 (7.9)
 Cis 11 (28.9)
 G1 15 (39.5)
 G2 9 (23.6)
 G3 9 (23.6)
Interval between last bladder cancer episode and urine marker sampling, months, Median (Range) 6 (3-84)
pT/Grade last bladder cancer episode before urine marker sampling, n (%)  
 pTa 74 (64.9)
 pT1 28 (24.5)
 Cis (pure) 12 (10.5)
 Cis (concomitant) 11 (9.6)
 G1 51 (44.7)
 G2 35 (30.1)
 G3 16 (14.0)
Highest pT/Grade in patient’s history before urine marker sampling, n (%)  
 pTa 71 (62.3)
 pT1 32 (27.3)
 Cis (pure) 11 (9.6)
 Cis (concomitant) 16 (14.0)
 G1 47 (41.2)
 G2 39 (34.2)
 G3 17 (14.9)
Time to recurrence, months, Median (Range) 12.5 (3-24)
Patients developing progression, n (%) 13 (11.4)
Time to progression, months, Median (Range) 11 (3-24)
  1. Cis = carcinoma in situ.